businesspress24.com - Merus Announces Closing of Private Placement
 

Merus Announces Closing of Private Placement

ID: 1235203

(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 06/10/13 -- Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL) (NASDAQ: MSLI) announces that it has completed its previously announced non-brokered private placement financing (the "Financing") of 7,678,034 shares at a price of $0.60 per share for gross proceeds of $4,606,820. The proceeds of the Financing are expected to be used by the Company for debt repayment and general corporate purposes.

These securities have not been registered under the U.S. Securities Act of 1933, as amended (the "Act"), and may not be offered or sold in the United States unless registered under the Act or unless an exemption from registration is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Merus Labs International Inc.

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.

Cautionary Statement

Certain statements contained in this press release may constitute "forward-looking statements", including statements regarding the use of proceeds of the Financing. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus' actual results to be materially different from any future results expressed or implied by these statements. Such factors include that Merus may not use the proceeds for the stated purpose. These forward-looking statements speak only as of the date of this press release, and Merus undertake no obligation to update or revise the statements.







Contacts:
Merus Labs International Inc.
Elie Farah
President and CEO
(416) 593-3701


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  SteadyMed Therapeutics, Inc. Further Strengthens Management Team With the Addition of Peter Noymer, Ph.D., Executive Vice President of R&D and Chief Technical Officer and Rick White, Vice President Business Development and Commercial Operations
LED Medical Diagnostics Inc.'s Patented VELscope(R) Vx Device Involved in Phase III Oral Cancer Study
Bereitgestellt von Benutzer: Marketwired
Datum: 10.06.2013 - 06:00 Uhr
Sprache: Deutsch
News-ID 1235203
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

TORONTO, ONTARIO


Phone:

Kategorie:

Medical Devices


Anmerkungen:


Diese Pressemitteilung wurde bisher 128 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Merus Announces Closing of Private Placement
"
steht unter der journalistisch-redaktionellen Verantwortung von

Merus Labs International Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Merus Labs International Inc.



 

Who is online

All members: 10 591
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 126


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.